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Summary
Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of 
tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 
pneumonia who received standard of care treatment.
Methods This retrospective, observational cohort study included adults (≥18 years) with severe COVID-19 pneumonia 
who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, 
and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the 
standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular 
weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given 
either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or 
subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the 
intravenous formulation was unavailable. The primary endpoint was a composite of invasive mechanical ventilation 
or death. Treatment groups were compared using Kaplan-Meier curves and Cox regression analysis after adjusting 
for sex, age, recruiting centre, duration of symptoms, and baseline Sequential Organ Failure Assessment (SOFA) score.
Findings Of 1351 patients admitted, 544 (40%) had severe COVID-19 pneumonia and were included in the study. 
57 (16%) of 365 patients in the standard care group needed mechanical ventilation, compared with 33 (18%) of 
179 patients treated with tocilizumab (p=0·41; 16 [18%] of 88 patients treated intravenously and 17 [19%] of 91 patients 
treated subcutaneously). 73 (20%) patients in the standard care group died, compared with 13 (7%; p<0·0001) patients 
treated with tocilizumab (six [7%] treated intravenously and seven [8%] treated subcutaneously). After adjustment for 
sex, age, recruiting centre, duration of symptoms, and SOFA score, tocilizumab treatment was associated with a 
reduced risk of invasive mechanical ventilation or death (adjusted hazard ratio 0·61, 95% CI 0·40–0·92; p=0·020). 
24 (13%) of 179 patients treated with tocilizumab were diagnosed with new infections, versus 14 (4%) of 365 patients 
treated with standard of care alone (p<0·0001).
Interpretation Treatment with tocilizumab, whether administered intravenously or subcutaneously, might reduce the 
risk of invasive mechanical ventilation or death in patients with severe COVID-19 pneumonia.
Funding None.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction
Since December, 2019, COVID-19 spread rapidly in 
Wuhan and throughout the Hubei province of China, and 
more recently in Europe and worldwide. Although a com-
parison of crude fatality rates across countries is made 
difficult by different testing policies, data from February 
and March, 2020, suggest that the fatality rate in Italy has 
been higher than that in China.1,2
The clinical presentation of COVID-19 is highly hetero-
geneous, ranging from asymptomatic to severe pneumonia 
with respiratory failure that could lead to invasive mech-
anical ventilation or death.3–5 The disease is characterised 
by an initial phase of viral replication that can be followed 
by a second phase driven by the host inflam matory 
response.6 Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection might cause a hyperimmune 
response that is associated with acute respiratory distress 
syndrome, as suggested by typical radiological findings.7 
The most critical patients can develop a so-called cyto-
kine storm, characterised by increased production of 
many cytokines that produce long-term damage and lung 
tissue fibrosis.8
No therapy has been approved for COVID-19 pneu-
monia, but current clinical approaches consider the 
combination of antiviral drugs and immunomodulatory 
drugs. Although lopinavir/ritonavir showed no benefit 
beyond the standard of care in an initial study,9 clinical 
trials on antivirals are ongoing. Drawing on a wider 
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immu nological perspective derived from rheumatology,10 
immunomodulatory drugs have been considered, such as 
selective cytokine inhibi tors, which leads to the inhibition 
of either the ligand or the receptor of a cytokine.11
Tocilizumab is a recombinant humanised monoclonal 
antibody of the IgG1 class, which is directed against 
both the soluble and membrane-bound forms of the 
interleukin-6 (IL-6) receptor.12,13 Tocilizumab is recom-
mended for the treatment of severe rheumatoid arthritis, 
systemic juvenile idiopathic arthritis, giant cell arteritis, 
and life-threatening cytokine release syndrome induced 
by chimeric antigen receptor T cell therapy.14–16 In a 
single-centre study from Wuhan, China,17 which included 
15 patients with COVID-19 pneumonia at risk for cytokine 
storm, treatment with tocilizumab appeared to have a 
clinical benefit, although doses ranged from 80 mg to 
600 mg. That study from China and other anecdotal 
observations18,19 resulted in the opportunity for off-label 
use of tocilizumab to treat patients with COVID-19 severe 
pneumonia in Italy. By May, an increas ing number of 
studies had reported use of tocilizumab in treating 
COVID-19.20,21
The aim of this multicentre cohort study was to assess 
the role of tocilizumab in reducing the risk of invasive 
mechanical ventilation or death in a cohort of patients 
with severe COVID-19 pneumonia who received standard 
of care treatment.
Methods
Study design and participants
The Tocilizumab in Patients with Severe COVID-19 
Pneumonia (TESEO) Study is a retrospective, observational 
cohort study done in three tertiary care centres in the 
Emilia-Romagna region, Italy, on patients with severe 
COVID-19 pneumonia. All centres contributed data on 
tocilizumab and standard of care treatment (appendix p 1). 
In the Modena cohort, we collected data on baseline signs, 
symptoms, comorbidities, blood count, and biochemical 
markers.
The study population was adults (≥18 years) with 
COVID-19, confirmed by PCR on nasopharyngeal swab, 
who were admitted to the centres in Bologna and 
Reggio Emilia between Feb 21 and March 24, 2020, and to 
the centre in Modena between Feb 21 and April 30, 2020 
(after reviewers requested a follow-up extension, which was 
only possible at the Modena centre). Eligible patients had 
severe pneumonia, defined as at least one of the following: 
presence of a respiratory rate of 30 or more breaths per 
minute, peripheral blood oxygen saturation (SaO2) of less 
than 93% in room air, a ratio of arterial oxygen partial 
pressure (PaO2) to fractional inspired oxygen (FiO2) of 
less than 300 mm Hg in room air, and lung infil trates 
of more than 50% within 24–48 h, according to Chinese 
management guidelines for COVID-19 (version 6.0).3,22
Exclusion criteria for the use of tocilizumab were 
coexistent infection other than COVID-19; a PaO2/FiO2 
ratio greater than 300 mm Hg; chronic or cur rent gluco-
corticoid use; history of severe allergic reactions to mono -
clonal antibodies; less than 500 per µL neutro phils or 
less than 50 × 10⁹ platelets; active diverticulitis, inflamma-
tory bowel disease, or another symptomatic gastrointestinal 
tract con dition that might predispose patients to bowel 
per fora tion; severe haematological, renal, or liver function 
impairment.
The study was approved by the Regional Ethical 
Committee of Emilia Romagna. All patients who received 
tocilizumab provided verbal, not written, informed con-
sent because of isolation precautions.
Procedures
All patients received standard of care treatment at the 
time of hospital admission according to the regional 
Research in context
Evidence before this study
No therapy is approved for COVID-19 pneumonia, but current 
clinical approaches consider the combination of antiviral and 
immunoactive drugs, including tocilizumab, a recombinant 
humanised monoclonal antibody against the interleukin-6 
receptor. Literature research was done through PubMed, 
Embase, Cochrane Review, ISI Web of Science, and SCOPUS up to 
May 31, 2020. This research revealed an increasing interest in 
tocilizumab use in COVID-19 pneumonia, but no randomised 
clinical trial has been published so far. In a single centre study 
from Wuhan, China, that included 15 patients with COVID-19 
pneumonia at risk for cytokine storm, treatment with 
tocilizumab appeared to have clinical benefit, although the 
doses were variable, ranging from 80 mg to 600 mg. A small, 
retrospective, case-control study from France found that death, 
intensive care unit admission, or both was higher in patients 
without tocilizumab than in the tocilizumab group (72% vs 25%; 
p=0·002). A randomised ongoing clinical study (CORIMUNO) 
anticipates a beneficial effect of tocilizumab compared with 
standard of care. 
Added value of this study
In our multicentre, retrospective study of 544 patients with 
severe COVID-19 pneumonia, the use of tocilizumab administered 
either intravenously or subcutaneously was associated with 
reduced risk of mechanical ventilation and death (adjusted hazard 
ratio 0·61, 95% CI 0·40–0·92; p=0·020). We also found a strong 
association between the use of tocilizumab and reduced risk of 
death (adjusted hazard ratio 0·38, 0·17–0·83; p=0·015).
Implications of all the available evidence
Tocilizumab, administered intravenously or subcutaneously, 
might be capable of reducing the risk of invasive mechanical 
ventilation or death in patients with severe COVID-19 
pneumonia.
See Online for appendix
Articles
e476 www.thelancet.com/rheumatology   Vol 2   August 2020
COVID-19 guidelines of Emilia Romagna23 and updated 
data on treatment of COVID-19.24 Standard of care 
treatment included oxygen supply to target SaO2 reach-
ing at least 90%, hydroxychloroquine (400 mg twice on 
day 1, followed by 200 mg twice per day on days 2–5, 
eventually adjusted for creatinine clearance estimated 
by a chronic kidney disease algorithm), azithromycin 
(500 mg once per day for 5 days) at the physician’s 
discretion when suspecting a bacterial respiratory super-
infec tion, lopinavir–ritonavir (400/100 mg twice per day) 
or darunavir–cobicistat (800/150 mg once per day) for 
14 days, and low molecular weight heparin for prophylaxis 
of deep vein thrombosis according to bodyweight and 
renal function.
In addition to receiving the standard of care treatment, 
a non-randomly selected subset of patients also received 
tocilizumab treatment. Patients were considered eligible 
for tocilizumab treatment if they showed SaO2 of less 
than 93% and a PaO2/FiO2 ratio of less than 300 mm Hg 
in room air or a more than 30% decrease in their 
PaO2/FiO2 ratio in the previous 24 h during hospitalisation. 
Tocilizumab was administered by the intravenous or 
subcutaneous route depending on the availability of 
specific formulation at time of treatment. It should be 
mentioned that during the observation period, the high 
national requirements created an intermittent shortage of 
both formulations of the drug. Therefore, a random 
subset of patients who were eligible for tocilizumab 
never received the drug because of unavailability. Intra-
venous tocilizumab was administered at 8 mg/kg body-
weight (up to a maximum of 800 mg) administered 
twice, 12 h apart. The second dose was given because 
pharmacokinetic data suggested that adequate plasma 
levels of the drug could be obtained only after two doses, 
based on the results of pharmacokinetic models for 
severe or life-threatening chimeric antigen receptor 
T cell-induced cytokine storm in adult and paediatric 
patients.25
The subcutaneous formulation was used when there 
was a shortage of the intravenous formulation, at a dose 
of 162 mg administered in two simultaneous doses, one 
in each thigh (ie, 324 mg in total). This approach was 
used to mimic, as much as possible, the pharmacokinetic 
acti vity of the intravenous formulation to achieve similar 
levels of drug exposure. Because the site and depth of 
subcutaneous injection can influence absorption and 
distribution,26 the rate of absorption might vary markedly 
between dosing sites.26 The peak plasma concentration 
might take a few days to be reached after a single 
subcutaneous dose because of slow absorption through 
the lymphatic system into the systemic circu lation.27 
Because the monoclonal antibody might undergo pro-
teolytic degradation by the cells of the reticulo endo-
thelial system,28 higher doses than usual subcutaneous 
dosing for other indications were provided through sep-
arate injections.27 This decision was supported by a 
comparative pharmacokinetic and pharmacodynamic 
study of subcutaneous versus intravenous tocilizumab, 
which showed that after a single 162 mg dose in healthy 
subjects, subcutaneous bioavailability was 48·8%, where-
as the pharmacodynamic activity of subcutan eous and 
intravenous tocilizumab against a soluble IL-6 receptor 
was similar during 1 week.28
The patients’ full medical history, chronic comorbid-
ities (including the Charlson Comorbidity Index29), demo-
graphic and epidemiological data, and baseline PaO2/FiO2 
ratio were obtained at hospital admission. Other treat-
ments were recorded, including glucocorticoids for acute 
respiratory distress syndrome. The risk of multiorgan 
failure and mortality was assessed with a standardised 
Sub sequent Organ Failure Assessment (SOFA) score.30 
Clinical data, including symptoms, complete blood count, 
coagulation, inflammatory, and biochemical markers were 
routinely registered in the electronic patient charts for the 
Modena cohort only.
Outcomes
The primary outcome of the study was a composite of 
death or invasive mechanical ventilation. The indica-
tions for mechanical ventilation were neurological failure 
(ie, altered consciousness with a Glasgow Coma Scale 
score of <10), cardiovascular failure (ie, vasopressor 
require ment or major electrocardiogram changes, includ-
ing arrythmia or changes in repolarisation phase), and 
respiratory failure, defined by the presence of at least two 
of the following criteria: respiratory rate of 30 or more 
breaths per minute, respiratory distress with activation of 
accessory respiratory muscles, the need for FiO2 at 80% or 
more to maintain a SaO2 level of 90%, or a PaO2/FiO2 ratio 
of less than 100 mm Hg.31,32
Statistical analysis
We compared the baseline characteristics of the partici-
pants treated with standard of care with tocilizumab and 
those treated with standard of care alone, including signs 
Figure 1: Overview of participants included in the TESEO cohort  
1351 patients admitted to recruiting centres
544 patients eligible for the study
807 patients excluded because 
did not satisfy the definition 
of severe pneumonia
179 patients treated with 
standard of care and 
non-randomly assigned to 
treatment with tocilizumab 
91 subcutaneous
88 intravenous
365 patients treated according to 
regional standard of care 
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and symptoms, existing comorbidities, and blood count 
markers. Continuous variables were expressed as median 
(IQR) and compared by the Mann-Whitney U test for 
two groups and Kruskal Wallis test for three groups. 
Categorical variables were expressed as numbers (%) and 
compared by the χ² test or Fisher’s exact test across 
the groups. In a secondary analysis, the group treated 
with standard of care and tocilizumab was further split 
into those who received subcutaneous or intravenous 
formulations of tocilizumab.
We did a standard survival analysis, following up 
partici pants from the date of entry into clinics until 
initiation of invasive mechanical ventilation or death. We 
compared the time to invasive mechanical ventilation or 
death by treatment group using unweighted Kaplan-Meier 
curves and univariable and multivariable Cox regression 
analysis with baseline fixed covariates. The effect of treat-
ment was shown using an unadjusted and adjusted 
hazard ratio (HR) with 95% CI. Key confounders were 
identified as sex, age, recruiting centre, duration of 
symptoms, and baseline SOFA score, which were the 
most probable causes of both treatment assignment and 
outcome risk.
To control for potential additional sources of time-fixed 
and time-varying confounding, we did various additional 
analyses. First, we adjusted the analysis for the baseline 
level of inflammation and coagulation in a subset of 
participants with available C-reactive protein and D-dimer 
values. Second, we replaced the SOFA score with alter-
native measures of the extent of concomitant morbidities 
at baseline, such as a binary indicator (≥1 comorbidity 
among diabetes, hypertension, cardiovascular disease, 
chronic renal insufficiency, or cancer) and the Charlson 
Comorbidity Index. Third, with the aim of emulating a 
ran domised trial with similar characteristics and appro pri-
ately controlling for the time-varying confounder of gluco-
corticoid use, we fitted a marginal structural Cox regres sion 
model with stabilised inverse probability weights, which 
were constructed using sex, age, SOFA score, recruit-
ing centre, duration of symptoms, time-varying use of 
glucocorticoids, and inverse probability of censor ing.33 A 
secondary analysis with an endpoint of death alone used 
both the cause-specific hazard approach (assuming non-
informative censoring) and a competing risk approach, 
in which deaths that occurred after the initiation of 
invasive mechanical ventilation were included as events.
Finally, to test the hypothesis that the difference between 
treatment groups might vary according to the baseline 
PaO2/FiO2 ratio, we formally included an interaction term 
in the Cox regression model. The results were shown after 
categorising the population into two strata using a clinical 
threshold of the PaO2/FiO2 ratio being 150 mm Hg. We also 
did a similar stratification analysis using age (18–64 years 
vs ≥65 years) to further investigate the possible con-
founding or effect modification caused by age.
In the subset of participants from the Modena cohort, 
we compared the mean trajectories of IL-6 (on a log10 
scale) and of aspartate aminotransferase (raw scale) over 
time between tocilizumab and standard of care, using a 
linear mixed model with random intercept and slope.
We considered a two-sided p value test of less than 0·05 
to be statistically significant. Statistical analyses were 
performed using the SAS software, version 9.4 (Cary, 
NC, USA).
Tocilizumab plus standard care group  
(n=179)
Standard care group 
(n=365)
p value All patients 
(n=544)
Subcutaneous (n=91) Intravenous (n=88) Overall (n=179)
Baseline characteristics
Age (years) 67 (55–73) 63 (54–72) 64 (54–72) 69 (57–78) 0·0064 67 (56–77)
Sex ·· ·· ·· ·· 0·088 ··
Female 28 (31%) 24 (27%) 52 (29%) 133 (36%) ·· 185 (34%)
Male 63 (69%) 64 (73%) 127 (71%) 232 (64%) ·· 359 (66%)
Baseline PaO2/FiO2 (mm Hg) 199 (123–262) 145 (102–229) 169 (106–246) 277 (191–345) <0·0001 239 (139–306)
Baseline SOFA score 2 (1–3) 3 (2–4) 3 (2–4) 2 (0–3) 0·0004 2 (1–4)
Duration of symptoms 
(days from symptom onset) 
8 (5–10) 4 (3–8) 7 (4–10) 5 (2–9) 0·0017 6 (3–9)
Outcomes
Follow-up (days) 12 (6–17) 13 (7–18) 12 (6–17) 8 (4–14) <0·0001 9 (4–15)
Events
Mechanical ventilation 17 (19%) 16 (18%) 33 (18%) 57 (16%) 0·41 90 (17%)
Deaths after mechanical 
ventilation*
2 (12%) 3 (19%) 5 (15%) 14 (25%) 0·51 19 (21%)
Death 7 (8%) 6 (7%) 13 (7%) 73 (20%) 0·0007 86 (16%)
Data are median (IQR) or n (%) unless otherwise indicated. The p values refer to differences between overall tocilizumab and standard of care and were calculated using the 
χ² test or Kruskal-Wallis test as appropriate. PaO2/FiO2=ratio of arterial oxygen partial pressure to fractional inspired oxygen. SOFA=Subsequent Organ Failure Assessment. 
*Percentages show the proportion of those who were mechanically ventilated.  
Table 1: Characteristics of patients from all centres combined
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Results
Of 1351 patients admitted to the recruiting centres, 
544 (40%) patients with severe pneumonia were included 
in our analysis (figure 1). Overall, 359 (66%) of the patients 
were male, with a median age of 67 years (IQR 56–77; 
table 1). All patients showed clinical deterioration, with a 
median SOFA score of 2 (IQR 1–4), mainly driven by 
respiratory failure and requirement of oxygen support. 
The SOFA scores and PaO2/FiO2 ratios at baseline differed 
substantially across centres, with patients in Modena 
being the most compromised (appendix p 1).
365 (67%) patients received standard of care treatment 
alone and 179 (33%) received treatment with tocilizumab 
in addition to standard of care (88 [16%] received intra-
venous and 91 [17%] subcutaneous tocilizumab; table 1). 
The standard of care group included older patients 
with less severe disease, and the group treated with 
intravenous tocilizumab included the most compromised 
patients, as shown by their PaO2/FiO2 ratios and SOFA 
scores (table 1). After baseline, 53 (30%) of 179 patients 
treated with tocilizumab started glucocorticoids versus 
61 (17%) of 365 patients in the standard of care group.
Data for comorbidities, signs, and symptoms were 
available for the patients from the Modena cohort only, 
which accounted for 354 (65%) of all patients (table 2). 
Among these patients, those treated with tocilizumab had 
a higher burden of hypertension and diabetes, and more 
had symptoms such as headache and cough (table 2). 
Biochemical markers were available for 304 (86%) of the 
patients in Modena, and showed that patients treated with 
tocilizumab had higher lactate dehydrogenase and worse 
inflammatory profiles at baseline, with higher C-reactive 
protein and IL-6 concentrations (table 3).
Overall, invasive mechanical ventilation was started in 
90 (17%) of 544 patients, including 57 (16%) of 365 patients 
in the standard care group versus 33 (18%) of 179 patients 
treated with tocilizumab (p=0·41; table 1). 86 (16%) of 
544 patients died, including 73 (20%) patients in the 
standard care group versus 13 (7%; p=0·0007) patients 
treated with tocilizumab (table 1). The percentage of 
patients who were ventilated differed by centre (p=0·028), 
but risk of mortality did not (p=0·49; appendix p 1). 
19 further deaths occurred after the date of initiation of 
mechanical ventila tion (two in the subcutaneous tocili-
zumab group, three in the intravenous tocilizumab group, 
and 14 in the standard of care group), giving a total 
of 105 deaths, which we analysed using a competing 
risk approach.
At 14 days from hospital admission, the cumulative 
proba bilities estimated with Kaplan-Meier analyses for all 
groups were 36·1% (95% CI 31·2–40·9) for the primary 
composite endpoint of invasive mechanical ventilation or 
death, 18·8% (15·1–22·5) for mechanical ventilation, and 
21·1% (16·3–25·8) for death (appendix p 7; figure 2).
Unweighted Kaplan-Meier estimates showed the bene-
ficial effect of treatment with tocilizumab compared with 
standard of care only (figure 2). At day 14 after hospital 
admission, the proportion of patients with the com-
posite outcome was 22·6% (95% CI 16·2–29·0) for 
the tocilizumab group versus 36·5% (30·7–42·2) for the 
standard of care only group (log rank p=0·0023; figure 2A; 
appendix p 7). The difference was larger and the 
association stronger for the mortality endpoint, both with 
the cause-specific hazard approach (log rank p<0·0001; 
figure 2C) and the competing risk approach (p<0·0001). 
After splitting the tocilizumab group by administration 
route, both groups showed a benefit compared with 
standard of care, with no marked difference between the 
intravenous and subcutaneous groups (log rank p=0·0091 
[figure 2B]; log rank p<0·0001 [figure 2D]).
Patients who received tocilizumab showed a significant 
reduction in risk of invasive mechanical ventilation or 
death when compared with those receiving standard of care 
only, as estimated from the unadjusted Cox regression 
model (HR 0·60, 95% CI 0·43–0·84; p=0·0030; table 4). 
After controlling for the key identified confounders of sex, 
age, SOFA score, recruiting centre, and duration of symp-
toms, the treatment effect was even larger (adjusted HR 
[aHR] 0·61, 0·40–0·92; p=0·020; table 4). These results 
Tocilizumab plus standard 
care group (n=132)
Standard care 
group (n=222)
p value All patients 
(n=354)
Subcutaneous 
(n=84)
Intravenous 
(n=48)
Age (years) 67 (56–73) 61 (52–74) 67 (55–78) 0·34 66 (55–76)
Sex ·· ·· ·· 1·0 ··
Female 26 (31%) 15 (31%) 68 (31%) ·· 109 (31%)
Male 58 (69%) 33 (69%) 154 (69%) ·· 245 (69%)
Any comorbidity 39 (46%) 24 (50%) 36 (16%) <0·001 99 (28%)
Comorbidities
Diabetes 11 (13%) 6 (13%) 7 (3%) 0·0008 24 (7%)
Hypertension 37 (44%) 22 (46%) 30 (14%) <0·0001 89 (25%)
Cardiovascular disease 9 (11%) 6 (13%) 12 (5%) 0·12 27 (8%)
Chronic renal 
insufficiency
2 (2%) 5 (10%) 7 (3%) 0·045 14 (4%)
Cancer 2 (2%) 0 8 (4%) 0·38 10 (3%)
Disease duration
Days from symptoms 
onset to hospitalisation
8 (6–11) 5 (3–9) 5 (2–9) 0·0016 7 (3–10)
Days from hospitalisation 
to intubation
3 (0–5) 2 (1–4) 2 (0–3) 0·49 2 (0–4)
Sign and symptoms
Fever (°C) 37 (36–38) 37 (36–38) 37 (36–37) 0·54 37 (36–37)
Cough 42 (50%) 20 (42%) 55 (25%) <0·0001 117 (33%)
Myalgia 5 (6%) 5 (10%) 7 (3%) 0·088 17 (5%)
Sputum 5 (6%) 0 4 (2%) 0·059 9 (3%)
Headache 5 (6%) 7 (15%) 10 (5%) 0·032 22 (6%)
Haemoptysis 0 1 (2%) 2 (1%) 0·45 3 (1%)
Systolic pressure (mm Hg) 130  
(118–138)
120  
(110–135)
124  
(110–140)
0·36 125  
(110–138)
Data are median (IQR) or n (%) unless otherwise indicated. p values were calculated using the χ2 test or Kruskal-Wallis 
test as appropriate.
Table 2: Baseline signs, symptoms, and comorbidities for patients at the Modena centre only
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were supported by various analyses that aimed to control 
for further sources of confounding, namely after adjust-
ing for baseline C-reactive protein values (aHR 0·57, 
0·38–0·84; p=0·0048) and baseline d-dimer levels 
(aHR 0·66, 0·42–1·05; p=0·082), after replacing the SOFA 
score with the Charlson Comorbidity Index (aHR 0·64, 
0·46–0·91; p=0·012), and after controlling for time-varying 
confounding of using glucocorticoids and informative 
censoring (aHR=0·53, 0·31–0·89; p=0·016; table 4).
The largest difference was found when comparing 
intravenously administered tocilizumab with standard of 
care only. After adjusting for the same set of identified 
confounders (ie, sex, age, and SOFA score, recruiting 
centre, and duration of symptoms), we estimated a reduc-
tion in the risk of invasive ventilation or death with an 
aHR of 0·55 (95% CI 0·31–0·98; p=0·042; table 4). For the 
composite endpoint, we found no evidence for a differ-
ence between subcutan eous and intravenous tocilizumab 
(aHR 1·18, 0·59–2·36; p=0·64; table 4). Finally, the main 
results for the composite endpoint were similar after 
restricting the analysis to people enrolled in Modena only 
(aHR 0·65, 0·43–0·99; p=0·044).
The formal test for interaction and the stratified 
analyses showed evidence that the different risk between 
tocilizumab and standard of care varied by baseline 
PaO2/FiO2 value (p=0·011). In particular, the effect of 
tocilizumab was greater in people with baseline PaO2/FiO2 
value of less than 150 mm Hg (aHR 0·19, 95% CI 
0·08–0·44; table 4). No difference in the results was 
found after controlling for age using stratification (aged 
18–65 years vs ≥65 years; data not shown).
With regard to mortality, a significant reduction in risk 
of death was found for tocilizumab treatment compared 
with standard of care treatment alone after controlling for 
sex, age, SOFA score, recruiting centre, and duration of 
symptoms (aHR 0·38, 95% CI 0·17–0·83; p=0·015; 
table 5). We found no statistical evidence for a differen-
tial benefit of tocilizumab by baseline PaO2/FiO2 value 
(interaction p=0·12; table 5), but the reduction in risk of 
death was stronger in people with a baseline PaO2/FiO2 
ratio of less than 150 mm Hg.
We also repeated this analysis after controlling for 
the Charlson Comorbidity Index instead of SOFA, and the 
results were similar (aHR 0·36, 95% CI 0·19–0·65; 
p=0·0008). Finally, after including the additional 19 deaths 
that occurred after the date of initiation of invasive 
ventilation, the results from the competing risk analysis 
were similar to those of the main analysis (aHR 0·27, 
0·16–0·47; p<0·0001).
The mixed linear models showed that IL-6 plasma levels 
were slightly higher at study entry in the tocilizumab 
group than in the standard of care group (2·46 log10 mg/L 
vs 2·25 log10 mg/L; p=0·091; appendix p 3). Over time, 
IL-6 was stable in the tocilizumab group and decreased in 
the standard of care group with a difference in slope of 
–0·02 log10 mg/L (95% CI –0·03 to –0·00; p=0·0042; 
appendix pp 3–4).
Adverse events were carefully monitored during 
the study period. In the tocilizumab group, one (<1%) 
patient had an episode of injection site reaction, with 
spontaneous resolution in a few hours. One (<1%) epi-
sode of severe neutropenia required granulocyte-colony 
Tocilizumab plus standard care group (n=125) Standard care group 
(n=179)
p value All patients (n=304)
Subcutaneous (n=78) Intravenous (n=47)
Haemoglobin (g/L) 12·8 (11·5–13·7) 13·0 (11·6–13·7) 12·7 (11·2–14·2) 1·0 12·7 (11·4–14·0)
White cells (mm³) 7195 (5470–10380) 6840 (5140–9380) 6200 (4570–9360) 0·22 6700 (4890–9560)
Lymphocytes (%) 22·1 (9·7–36·8) 18·1 (12·5–25·8) 23·1 (9·9–39·7) 0·60 20·6 (9·9–36·6)
Total lymphocytes (mm³) 1580 (1390–2142) 2459 (1852–3348) 1390 (1000–2815) 0·30 1852 (1120–2726)
Platelets (10⁹/L) 257·5 (183·0–374·0) 211·0 (156·0–294·0) 209·0 (155·0–298·0) 0·0027 221·5 (163·0–317·0)
Alanine aminotransferase (U/L) 37·0 (27·0–71·0) 35·0 (21·5–62·5) 31·0 (19·0–48·0) 0·0070 33·0 (22·0–56·0)
Bilirubin (mg/L) 0·6 (0·4–0·7) 0·6 (0·4–0·8) 0·6 (0·4–0·8) 0·74 0·6 (0·4–0·8)
Calcium (mg/L) 8·6 (8·4–9·1) 8·5 (8·1–8·9) 8·6 (8·3–9·1) 0·26 8·6 (8·3–9·1)
Creatine kinase (U/L) 63·0 (33·0–159·0) 130·0 (41·5–312·0) 71·0 (39·0–202·0) 0·051 76·0 (38·0–197·5)
Chloride (mmol/L) 101·0 (98·0–105·0) 100·0 (99·0–103·0) 101·0 (97·0–103·0) 0·91 101·0 (98·0–103·0)
Creatinine (mg/L) 0·8 (0·6–0·9) 0·9 (0·7–1·2) 0·9 (0·7–1·1) 0·0050 0·8 (0·7–1·1)
D-dimer (mg/L) 1210 (820·0–2290) 1000 (780·0–2730) 1240 (610·0–2480) 0·64 1200 (690·0–2480)
Lactate dehydrogenase (U/L) 600·0 (505·0–761·0) 676·0 (536·0–765·0) 507·5 (419·5–705·5) 0·0002 564·0 (454·0–745·0)
Potassium (mmol/L) 3·9 (3·5–4·3) 3·8 (3·6–4·0) 3·9 (3·5–4·3) 0·34 3·9 (3·5–4·2)
Sodium (mmol/L) 137·5 (136·0–139·0) 137·0 (135·0–138·0) 138·0 (135·0–141·0) 0·019 138·0 (135·0–140·0)
Ferritin (mg/L) 1168 (543–1214) ·· 423 (355–993) 0·14 447 (355–1141)
C-reactive protein (mg/L) 3·4 (0·6–7·8) 6·1 (1·8–15·3) 5·4 (1·8–14·6) 0·022 5·3 (1·4–13·6)
Interleukin-6 (mg/L) 190·2 (86·6–401·0) 238·3 (140·2–731·9) 144·1 (41·1–385·8) 0·045 178·6 (67·6–402·0)
Data are median (IQR). p values were calculated using the Kruskal-Wallis test.
Table 3: Baseline blood count and biochemical markers for patients at the Modena centre only
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stimulating factor administration. Finally, there was 
no evidence for a difference in the rate of increase of 
aspartate aminotransferase between treatment groups 
(appendix pp 5–6). There was only one (<1%) patient in 
the standard of care group whose aspartate amino-
transferase concentrations increased from 19 U/L before 
treatment level to 139 U/L at 6 days after treatment, and 
none in the tocilizumab group.
We paid careful attention to new episodes of infections 
in the tocilizumab and standard of care groups, which 
inclu ded bloodstream infections (three vs four), bacterial 
pneumonia (eight vs six), candidemia (two vs two), urinary 
tract infection (one vs one), Pneumocistis jirovecii pneu-
monia (one vs one), invasive aspergillosis, (four vs none), 
hepatitis B virus reactivation (one vs none), and herpes 
simplex virus 1 reactivation (four vs none). Of note, 
one (<1%) severe adverse event occurred in the tocilizumab 
group 12 days after subcutaneous injection, consisting of 
severe liver failure due to herpes simplex virus 1 reactiva-
tion, leading to death. This patient received high-dose 
glucocorticoids after the administration of tocilizumab. 
Overall, 24 (13%) of 179 patients treated with tocilizumab 
were diagnosed with new infections, versus 14 (4%) of 
365 patients treated with standard of care alone (p<0·0001).
Discussion
In the real-life setting of the TESEO cohort, we found a 
significant reduction in risk of invasive mechanical 
ventilation or death in patients with severe COVID-19 
pneumonia who were treated with either intravenous or 
subcutaneous tocilizumab and standard of care, compared 
with those treated with standard of care only. The associ-
ation with the use of tocilizumab was stronger when 
overall mortality risk was analysed alone.
Our results are consistent with those of a smaller, retro-
spective, case-controlled French study by Klopfenstein and 
Figure 2: Kaplan-Meier estimates of the cumulative probability of mechanical ventilation or death (A, B) and death (C, D) by treatment group 
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colleagues,20 in which death or intensive care unit (ICU) 
admissions were higher in patients who did not receive 
tocilizumab than those who did (72% vs 25%; p=0·002). 
The CORIMUNO random ised clinical trial, from which 
some data are already available, also anticipates a bene-
ficial effect of tocilizumab when compared with standard 
of care.34
The natural history of severe COVID-19 pneumonia is 
thought to be driven by a so-called cytokine storm.14 Never-
theless, current recommendations do not include any 
immunologically active drug in routine clinical practice, 
and use of glucocorticoids is controversial.35,36 Tocilizumab, 
administered intravenously or subcutan eously, can be 
considered together with anakinra as one of the immuno-
modulatory drugs that have been tested in clinical care for 
the treatment of severe COVID-19 pneumonia.19–21,37 In the 
present study, IL-6 levels remained stable after tocilizumab 
administration but decreased in people receiving standard 
of care only. This finding was expected because tocilizumab 
competitively blocks IL-6 receptors and leaves free IL-6 
in plasma. Longer follow-up and larger sample sizes 
are needed to better understand the prognostic role of 
IL-6 concentrations and other biomarkers in patients with 
COVID-19 pneumonia who are treated with tocilizumab.
The real-life setting, including three different hospitals, 
accounted for the heterogenicity in clinical character-
istics and disease severity across intervention groups. As 
expected, the comparator group showed a higher baseline 
PaO2/FiO2 value than did the intervention group. Thus, in 
the unadjusted analysis the magnitude of the beneficial 
effect associated with the use of tocilizumab could have 
been underestimated. We attempted to control for this 
confounding bias by adjusting for SOFA score, which 
includes baseline PaO2/FiO2, and the difference was 
indeed larger after adjustment. In addition, the effect of 
tocilizumab was at least two times higher in people with a 
baseline PaO2/FiO2 ratio of less than 150 mm Hg, implying 
that the benefit of tocilizumab could be greater in patients 
with a greater risk of death or mechanical ventilation. 
Further studies are needed to evaluate the optimal timing 
of tocilizumab initiation on the basis of PaO2/FiO2 values 
and severity of disease stage.
Our results were similar after further adjusting for post-
baseline use of glucocorticoids. This analysis opens the 
discussion for the combination of immunomodulatory 
drugs (ie, monoclonal antibodies) with anti-inflammatory 
drugs (ie, glucocorticoids and non-steroid anti-inflam-
matory drugs). Importantly, very similar results were 
obtained regardless of the route of tocilizumab admin-
istra tion. Nevertheless, we cannot rule out the presence of 
other time-varying confounders that were affected by the 
chosen treatment strategy and were not accounted for in 
the analysis. Of note, antiviral drugs (protease inhibitors 
such as lopinavir–ritonavir and darunavir–cobicistat) 
were used in both groups and were never started after 
baseline in the tocilizumab group.
Unadjusted analysis Adjusted analysis* Adjusted analysis†
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Overall (two-way contrast)
Standard of care 1 (ref) ·· 1 (ref) ·· 1 (ref) ··
Tocilizumab (any) 0·60 (0·43–0·84) 0·0030 0·64 (0·45–0·91) 0·012 0·61 (0·40–0·92) 0·020
Tocilizumab (any)‡ 0·54 (0·37–0·78) 0·0009 ·· ·· 0·53 (0·31–0·89)§ 0·016
Baseline PaO2/FiO2 ≤150 mm Hg (two-way contrast)
Standard of care 1 (ref) ·· 1 (ref) ·· 1 (ref) ··
Tocilizumab (any)¶ 0·30 (0·17–0·52) ·· 0·20 (0·11–0·36) ·· 0·19 (0·08–0·44) ··
Interaction p value ¶ ·· ·· ·· ·· ·· 0·011
Baseline PaO2/FiO2 >150 mmHg (two-way contrast)
Standard of care 1 (ref) ·· 1 (ref) ·· 1 (ref) ··
Tocilizumab (any)¶ 0·31 (0·16–0·59) ·· 0·39 (0·20–0·77) ·· 0·46 (0·21–0·99) ··
Overall comparison (three-way contrast)
Standard of care 1 (ref) ·· 1 (ref) ·· 1 (ref) ··
Subcutaneous tocilizumab 0·63 (0·41–0·97) 0·036 0·69 (0·44–1·08) 0·102 0·65 (0·39–1·11) 0·11
Intravenous tocilizumab 0·57 (0·36–0·90) 0·016 0·60 (0·38–0·95) 0·030 0·55 (0·31–0·98) 0·042
Intravenous tocilizumab 1 (ref) ·· 1 (ref) ·· 1 (ref) ··
Subcutaneous tocilizumab 1·10 (0·61–1·95) 0·76 1·14 (0·63–2·05) 0·67 1·18 (0·59–2·36) 0·64
Standard of care 1·75 (1·11–2·75) 0·016 1·66 (1·05–2·62) 0·030 1·80 (1·02–3·19) 0·042
Data are n (95% CI) unless otherwise indicated. Data obtained using a Cox regression model. 152 patients with missing PaO2/FiO2 were not included in the stratified analysis. 
PaO2/FiO2=ratio of arterial oxygen partial pressure to fractional inspired oxygen. *Adjusted for age, sex, and recruiting centre. †Adjusted for age, sex, recruiting centre, duration of 
symptoms, and Subsequent Organ Failure Assessment (SOFA) score. ‡Using a weighted Cox instead of standard Cox model. §Adjusted for age, sex, recruiting centre, duration of 
symptoms, SOFA score, use of steroids after baseline, and censoring using inverse probability weighting. ¶Some p values intentionally left out as p values in the subsets are 
not interpretable.
Table 4: Unadjusted and adjusted relative hazards of the composite of the initiation of invasive mechanical ventilation or death
Articles
e482 www.thelancet.com/rheumatology   Vol 2   August 2020
A major concern is adverse events. We observed a signi-
ficantly higher prevalence of infection in the tocilizumab 
group than in the standard of care only group. The study 
design and short follow-up period do not allow us to make 
conclusions regarding the early and long-term side-effects 
of receiving tocilizumab followed by glucocorticoids; data 
from ongoing randomised clinical trials are required. 
Nevertheless, the case of severe herpes simplex virus 1 
hepatitis in the tocilizumab group suggests the impor-
tance of screening for herpes virus reactivation, especially 
if glucocorticoids are added.
We chose a composite outcome including both invasive 
mechanical ventilation and all-cause mortality. The crude 
fatality rate in our cohort was 16% (86 deaths before 
mechanical ventilation and 105 [19%] deaths in total 
among 544 patients diagnosed with severe pneumonia). A 
large multicentre cohort study from China showed a 
fatality rate of 28% among hospitalised patients, despite 
patients being younger by a median of 15 years compared 
with our study.3 Moreover, in a study conducted in Wuhan, 
China, 84 (42%) of 201 patients developed acute respiratory 
distress syndrome, and 44 (52%) of them died.1 In the 
European setting, a recent large study38 with 1591 patients 
admitted to ICUs in the Lombardy region of Italy showed 
that 1150 (88%) received mechanical ventilation, 137 (11%) 
received non-invasive ventilation, and the fatality rate 
was 26%.38 However, this analysis did not exclude patients 
who were still hospitalised and did not evaluate patients 
outside of the ICU setting and is therefore not fully 
comparable with our findings.
Our composite endpoint allowed us to describe not only 
the most critical clinical events, but also the most 
burdensome issue for health-care systems that need to 
rapidly increase the availability of their ICU resources. It 
is important to note that many countries are facing a 
shortage of mechanical ventilators. This shortage could 
lead to difficult clinical choices about which patients to 
prioritise for treatment. Consequentially, a treatment that 
reduces ICU admission is highly relevant not only to 
ameliorate the prognosis of the hospitalised patients, but 
also to give more patients the opportunity to receive 
intensive care when needed. However, the largest effect of 
the tocilizumab treatment in the present study was for 
mortality, and rates of mech anical ventilation alone made 
little contribution to the difference observed. 
Our study has some limitations. First, it is not a 
randomised comparison, and therefore unmeasured con-
founding cannot be ruled out. In addition, the results rely 
on the usual assumptions about the model being correctly 
specified (ie, that the assumed underlying causal structure 
is correct and we have adjusted for all sources of measured 
confounding). The participants who received standard of 
care only were older and therefore at higher baseline risk 
of invasive ventilation and death. However, these patients 
were also more likely to be women, and female sex has 
been shown to be associated with better outcomes.39 The 
patients who received tocilizumab in addition to standard 
of care treatment were mainly selected based on the 
availability of the drug (which was intermittent over the 
recruitment phase because of shortages), and they were 
more compromised patients with lower PaO2/FiO2 ratios 
and higher SOFA scores compared with those treated 
with standard of care alone. We adjusted the analy-
sis for SOFA, which controls for respiratory func tion 
(baseline PaO2/FiO2 ratio) and separately for the Charlson 
Comorbidity Index (which controls for the extent of 
Unadjusted analysis Adjusted analysis* Adjusted analysis†
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Overall comparison (two-way contrast)
Standard of care 1 (ref) ·· 1 (ref) ·· 1 (ref) ··
Tocilizumab (any) 0·28 (0·15–0·50) <0·0001 0·36 (0·20–0·66) 0·0009 0·38 (0·17–0·83) 0·015
Baseline PaO2/FiO2 ≤150 mmHg (two-way contrast)
Standard of care 1 (ref) ·· 1 (ref) ·· 1 (ref) ··
Tocilizumab (any)‡ 0·11 (0·04–0·27) ·· 0·09 (0·03–0·24) ·· 0·03 (0·00–0·24) ··
Interaction p value‡ ·· ·· ·· ·· ·· 0·12
Baseline PaO2/FiO2 >150 mmHg (two-way contrast)
Standard of care 1 (ref) ·· 1 (ref) ·· 1 (ref) ··
Tocilizumab (any)‡ 0·22 (0·08–0·63) ·· 0·39 (0·12–1·20) ·· 0·44 (0·11–1·73) ·· 
Overall comparison (three-way contrast)
Standard of care 1 (ref) ·· 1 (ref) ·· 1 (ref) ··
Subcutaneous tocilizumab 
subcutaneous
0·30 (0·14–0·66) 0·0025 0·37 (0·17–0·83) 0·016 0·44 (0·17–1·14) 0·091
Intravenous tocilizumab 0·25 (0·11–0·58) 0·0012 0·35 (0·15–0·80) 0·013 0·29 (0·09–0·99) 0·048
Data are n (95% CI) unless otherwise indicated. Data obtained using a Cox regression model. 152 patients with missing PaO2/FiO2 were not included in the stratified analysis. 
PaO2/FiO2=ratio of arterial oxygen partial pressure to fractional inspired oxygen. *Adjusted for age, sex, and recruiting centre. †Adjusted for age, sex, recruiting centre, 
duration of symptoms, and Subsequent Organ Failure Assessment (SOFA) score. ‡Some p values intentionally left out as p values in the subsets are not interpretable.
Table 5: Unadjusted and adjusted relative hazards of death (all-cause mortality)
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comorbidities present at admission). In the tocilizumab 
group, there were two patients with cancer and two 
patients with renal insufficiency, and in the standard of 
care group, there were eight patients with cancer and 
seven with chronic renal insufficiency. Therefore, we 
cannot rule out residual confounding that cannot be 
controlled by regression interpolation.
Another limitation is that although the key confounder 
measurements (for sex, age, SOFA score, duration of 
symptoms, and Charlson Comorbidity Index) were 
available for all participants, this was not true for some of 
the biomarkers of inflamma tion and coagulation, which 
were available for only the par ticipants in Modena. 
However, the results were similar when we repeated the 
analysis using the Modena centre dataset alone. Impor-
tantly, when we used a marginal struc tural model instead 
of the standard estimate of the hazard ratio that is 
conditioned on covariates, which addi tionally controlled 
for glucocorticoid use after baseline, the differ ence in risk 
between treatment strategies was even larger. This is a key 
result, given the wide use of these methods, the time-
varying structure of the data, and our attempt to emulate 
the results of randomised comparisons.33
The study was also open label, so that staff involved 
knew which patients were receiving tocilizumab. This 
knowledge might have led to variability in the decision of 
when to move a patient to invasive ventilation (ie, a 
quicker decision for those receiving standard of care only). 
Moreover, it should be acknowledged that the indication 
for mechanical ventilation, even if suggested by guide-
lines, still relies on clinical judgment, which might vary 
according to experience and the availability of resources. 
The ICU staff involved in the study shared similar 
protocols and resources. Finally, because of the short 
follow-up period, we were not able to assess long-term 
safety and adverse effects. Further studies are needed to 
define appropriate dosing and minimise the side-effects.
Our study has also strengths. First, it was a large study 
that included patients from a real-life hospital setting. 
Second, key confounding factors were collected daily 
in a standardised way for a minimum of 14 days and 
were linked to the electronic charts of blood counts 
and clinical data.
Many questions remain open. The generalisability 
of the results must be considered in relation to differ-
ent epidemiological settings, particularly regarding the 
tocilizumab dose and use at the appropriate time point of 
the disease course. Other drugs that act directly in the 
inflammatory response pathway triggered in COVID-19 
are being tested. Tocilizumab use in severe COVID-19 
pneu monia is still in its infancy, and the best treatment 
strate gies have yet to be developed. For instance, our 
experience also described subcutaneous tocilizumab use, 
which warrants future studies in out-patient settings.
In conclusion, both intravenous and subcutaneous 
tocilizumab administration might be capable of reducing 
the risk of invasive mechanical ventilation or death in 
patients with severe COVID-19 pneumonia. Although 
these results are encouraging, they should be confirmed 
in ongoing randomised studies.
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